Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Buy” from Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $11.67.

Several brokerages recently weighed in on ACRS. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. Scotiabank began coverage on Aclaris Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective on the stock. Cantor Fitzgerald began coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an “overweight” rating for the company. Finally, HC Wainwright upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Monday, December 23rd.

Institutional Trading of Aclaris Therapeutics

A number of institutional investors have recently bought and sold shares of the company. ExodusPoint Capital Management LP acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth $26,000. Invesco Ltd. purchased a new position in Aclaris Therapeutics during the 4th quarter valued at about $28,000. Graham Capital Management L.P. acquired a new position in Aclaris Therapeutics during the fourth quarter worth about $35,000. Commonwealth Equity Services LLC purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at about $36,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $38,000. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Stock Down 1.9 %

ACRS opened at $1.59 on Friday. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17. The business has a 50 day moving average price of $2.08 and a two-hundred day moving average price of $2.22. The company has a market cap of $171.59 million, a PE ratio of -3.06 and a beta of 0.48.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.